sto public sale

DISCLAIMER: Purchase of RDG Tokens is NOT considered accepted until Radiologex notifies the investor that its subscription agreement has been accepted (but in no event less than 75 days), and can be refused for any reason or no reason including but not limited to: any regulatory reasons, deficiency in KYC, or other investor screening reasons, all being in the sole and absolute discretion of Radiologex. The funds are accepted in units of United States of America (USA) dollars and refunded in units of USA dollars, irrespective of the medium in which they are paid. In the case they are sent or received in accepted forms of crypto currency or other country's fiat currency, the conversion will be at any commercially-reasonable exchange rate at the moment of receipt or refund.

ALL Securities sold subject to max of 50M tokens sold or $20m raised whichever comes first.

This communication does not constitute an offer or a solicitation to purchase securities, as that term is defined in the United States under the Securities Act of 1933 (“the Act”), or in any other jurisdiction. A definitive offer to purchase or sell securities can only be made through long-form offering documents including a Subscription Agreement. Any decision to purchase security tokens in connection with a prospective offering should be made solely on the basis of the information contained in any then-current Offering Circular, Subscription Agreement, and ancillary documents, which should be carefully-reviewed and evaluated in consultation with the prospective purchaser's legal, accounting, investment, tax and any other applicable advisors, in view of the prospective purchaser's circumstances. For avoidance of doubt, this communication does not constitute a purchase recommendation regarding any security tokens proposed or intended to be offered or sold by Radiologex Technologies, LLC.

Note Regarding Forward-Looking Statements Radiologex cautions that statements in this communication that are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties that may impact actual results of operations and prospective transactions. These forward-looking statements include, among other things, statements about the health information technology and blockchain markets and the offer and consummation of contemplated transactions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Such statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, without limitation: the risk of divergent business climate, health care sector and/or health information technology developments; the risk that anticipated transaction(s) may fail to obtain due to factors outside of our control; the outcome of any legal proceedings, regulatory proceedings or enforcement matters; adverse changes in the funding markets (including the markets for blockchain security tokens); and changes in the terms, scope or timing of contracts, contract cancellations, and other modifications and actions by customers and other business counterparties of LK Group, Inc. or Radiologex, LLC. If one or more of these or unknown risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of Radiologex’s management as of the date hereof. Except to the extent required by applicable law, Radiologex undertakes no obligation to update or revise any forward-looking statement.